Status:
COMPLETED
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Lead Sponsor:
Rhythm Pharmaceuticals, Inc.
Conditions:
Bardet-Biedl Syndrome
POMC Deficiency
Eligibility:
All Genders
6+ years
Phase:
PHASE3
Brief Summary
A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway.
Detailed Description
This study is designed to compare the safety, pharmacokinetics, and efficacy of weekly and daily formulations of setmelanotide in participants with obesity associated with biallelic or heterozygous PO...
Eligibility Criteria
Inclusion
- Key
- Biallelic or heterozygous POMC/PCSK1 or LEPR (PPL) genetic variants or Bardet-Biedl syndrome (BBS), for which they are being treated with QD setmelanotide.
- 6 years or older at screening.
- Taking the setmelanotide QD formulation for at least 6 months in the RM-493-022 (NCT03013543) study with acceptable safety and tolerability, and dose level.
- Participant and/or parent or guardian is able to communicate well with the Investigator, to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent.
- Use of a highly effective form of contraception throughout the study and for 90 days following the study.
- Key
Exclusion
- Glycosylated hemoglobin (HbA1C) \>9.0% at screening.
- Anti-obesity medications within 3 months prior to starting the Run-in Period.
- History of significant liver disease or liver injury.
- Glomerular filtration rate \<30 milliliter per minute (mL/min).
- Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions.
- Major psychiatric disorders.
- Any suicidal ideation or behavior, or any lifetime history of a suicide attempt.
- Significant hypersensitivity to any excipient in the study drug.
- Inability to comply with the QW and QD injection regimens.
- Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing, with the exception of a setmelanotide clinical trial.
- Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
December 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 19 2023
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT05194124
Start Date
December 21 2021
End Date
October 19 2023
Last Update
November 26 2024
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Honor Health Research Institute
Scottsdale, Arizona, United States, 85258
2
Marshfield Clinic Research Institute
Marshfield, Wisconsin, United States, 54449
3
Alberta Health Services
Edmonton, Alberta, Canada, T6G 2E1
4
Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum
Berlin, Germany, 13353